Place in therapy of anti-IL-17 and 23 in psoriasis according to the severity of comorbidities: a focus on cardiovascular disease and metabolic syndrome-Reference-Cited by-同舟云学术

Place in therapy of anti-IL-17 and 23 in psoriasis according to the severity of comorbidities: a focus on cardiovascular disease and metabolic syndrome

Published:2022-06-26 Issue:12 Volume:22 Page:1443-1448
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Trovato Emanuele¹^ORCID,Rubegni Pietro¹,Prignano Francesca²

Affiliation:

1. Unit of Dermatology, Department of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy

2. Dermatology Section, Department of Health Sciences, University of Florence, Florence, Italy

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2022.2093106

Reference50 articles.

1. Harmonizing the Metabolic Syndrome

2. Metabolic profiling reveals interleukin-17A monoclonal antibody treatment ameliorate lipids metabolism with the potentiality to reduce cardiovascular risk in psoriasis patients

3. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database

4. The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events

5. Psoriasis, metabolic syndrome and cardiovascular risk factors. A population‐based study

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Residual metabolic burden in young psoriasis patients successfully treated with biologics;2024-09-02

2. From Psoriasis to Psoriatic Arthritis: Decoding the Impact of Treatment Modalities on the Prevention of Psoriatic Arthritis;Rheumatology and Therapy;2024-06-07

3. Therapeutic Potential of Targeting the JAK/STAT Pathway in Psoriasis: Focus on TYK2 Inhibition;Journal of Clinical Medicine;2024-05-24

4. Cardiovascular Considerations and Implications for Treatment in Psoriasis: An Updated Review;Vascular Health and Risk Management;2024-05

5. Comorbidities among adult patients with psoriasis in Tianjin: a cross-sectional analysis of the Health Database study;BMJ Open;2024-05